Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

14.55USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$14.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
38,418
52-wk High
$18.00
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 23 May 2018 04:15pm EDT 

May 23 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.EIGER BIOPHARMACEUTICALS - PLANS TO USE NET PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB IN HEPATITIS DELTA VIRUS INFECTION, OTHERS.  Full Article

Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results
Friday, 11 May 2018 08:00am EDT 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.84.Q1 EARNINGS PER SHARE VIEW $-1.04 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, EIGER HAD CASH, CASH EQUIVALENTS AND SHORT-TERM DEBT SECURITIES OF $33.2 MILLION.  Full Article

Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​
Wednesday, 21 Mar 2018 08:00am EDT 

March 21 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM.EIGER BIOPHARMACEUTICALS INC - ‍PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018​.EIGER BIOPHARMACEUTICALS INC - PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018.EIGER BIOPHARMACEUTICALS INC - EXPECT TO SHARE ADDITIONAL INFORMATION ON PLANNED REGISTRATION PROGRAM IN 2Q 2018.EIGER BIOPHARMACEUTICALS - ‍LIFT ENROLLMENT PLANNED FOR 2Q 2018​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 08:00am EST 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 09:07am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 09:17am EDT 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article

Eiger BioPharmaceuticals announces proposed public offering of common stock
Thursday, 26 Oct 2017 04:30pm EDT 

Oct 26 (Reuters) - Eiger BioPharmaceuticals Inc :Eiger BioPharmaceuticals announces proposed public offering of common stock.Eiger BioPharmaceuticals - ‍intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates​.  Full Article

Eiger says FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Eiger Biopharmaceuticals Inc ::Eiger announces FDA orphan drug designation granted for pegylated interferon lambda in hepatitis delta virus infection.  Full Article

Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals
Tuesday, 22 Aug 2017 01:35pm EDT 

Aug 22 (Reuters) - Sphera Funds Management Ltd::Sphera Funds Management Ltd reports a 5.35 percent passive stake in Eiger Biopharmaceuticals Inc as of August 17, 2017 - SEC Filing​.  Full Article